Ga
No verificado

Galderma

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaSaludSanidad
02/11/2026
Web y redes sociales
Mercado laboral
Telefonía
Biotecnología
Finanzas
Salud
Asociaciones/Profesionales
Farmacéutica
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition
1.00
23/10/2026
Biotecnología
Salud
Medicina - Varios
Sanidad
Industria
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
1.00
21/10/2026
Biotecnología
Farmacéutica
Salud
Eventos
Industria
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership
1.00
15/10/2026
Multimedia
Ciencia
Infancia
Medicina - Varios
Biotecnología
Sanidad
Salud
Ir de compras
Farmacéutica
Eventos
Ferias y Congresos
Industria
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
1.00
14/10/2026
Multimedia
Biotecnología
Sanidad
Salud
Moda
Cosmética
Venta al público/Minorista
Mercado de valores
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering
1.00
13/10/2026
Multimedia
Ciencia
Medicina - Varios
Sanidad
Farmacéutica
Ir de compras
Salud
Cosmética
Venta al público/Minorista
Industria
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing
1.00
08/10/2026
Eventos
Ferias y Congresos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older
1.00
06/10/2026
Multimedia
Industria
Salud
Material médico sanitario
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation
1.00
30/09/2026
Multimedia
Ferias y Congresos
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0